Envíe este artículo por correo electrónico 
Impacto de tratamiento antirretroviral: inhibidores de integrasa en la prevalencia de síndrome metabólico en pacientes con VIH
Resumen
El VIH es una infección que requiere tratamiento de por vida, incluye medicamentos con interacciones deletéreas en el metabolismo, los inhibidores de la integrasa, aparentemente ofrecen menor riesgo para desarrollar síndrome metabólico. Esta revisión sistemática resume el conocimiento sobre la asociación entre los inhibidores de la integrasa y síndrome metabólico en individuos con VIH. Caracterizar el impacto de los inhibidores de la integrasa en la prevalencia de síndrome metabólico. La búsqueda incluyó las bases de datos PubMED, LILACS y Cochrane Library. Para el análisis se llevó a cabo una búsqueda que arrojó 54 trabajos, 18 fueron eliminados por ser duplicados, 7 se eliminaron por título y resumen, 30 artículos se estudiaron completamente y se eliminaron 4 artículos por criterios de exclusión, se escogieron finalmente 26. El tratamiento antirretroviral en pacientes con VIH se vincula a mayor síndrome metabólico que en no tratados. El cambio de tratamiento a inhibidores de la integrasa mejora el perfil de seguridad para desarrollar síndrome metabólico. Todos los tratamientos para el VIH influyen en la homeostasis metabólica, aumentando el riesgo de síndrome metabólico. Sin embargo, los inhibidores de la integrasa, especialmente raltegravir, se destacan como opciones más seguras.
Recibido: 14 de Julio de 2024.
Aceptado: 16 de Febrero de 2025.
Palabras clave
Texto completo:
PDFReferencias
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021; 74: 790-9. doi: 10.1016/j.rec.2021.07.010. Erratum in: ev Esp Cardiol (Engl Ed). 2022;75: 192. doi:10.1016/j.rec.2021.10.019. [PubMed] [Google Scholar]
Calza L, Colangeli V, Magistrelli E, Rossi N, Rosselli Del Turco E, Bussini L, Borderi M, Viale P. Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment. HIV Clin Trials. 2017; 18: 110-7. doi: 10.1080/15284336.2017.13115027. [PubMed] [Google Scholar]
Hulgan T. Factors associated with insulin resistance in adults with HIV receiving contemporary antiretroviral therapy: A brief update. Curr HIV/AIDS Rep [Internet]. 2018; 15: 223–32.
http://dx.doi.org/10.1007/s11904-018-0399-7. [PubMed] [Google Scholar]
Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, Horberg MA, Matthews WC, Silverberg MJ, Thorne J, Mayor AM, Lima VD, Palella FJ, Saag MS, Althoff KN, Gill MJ, Wong C, Klein
MB, Crane HM, Marconi VC, Shepherd BE, Sterling TR, Koethe JR. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clin Infect Dis. 2021; 73: e2234-e2242. doi: 10.1093/cid/ciaa1403..
http://dx.doi.org/10.1093/cid/ciaa1403. [PubMed] [Google Scholar]
Mulindwa F, Kamal H, Castelnuovo B, Byonanebye DM, Schwarz JM, Bollinger R, Brusselaers N. Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and metaanalysis. BMJ Open Diabetes Res Care. 2023; 11: e003136. doi: 10.1136/bmjdrc-
-003136. http://dx.doi.org/10.1136/bmjdrc-2022-003136. [PubMed] [Google Scholar]
Koethe JR, Moser C, Brown TT, Stein JH, Kelesidis T, Dube M, Currier J, McComsey GA. Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s. Clin Infect Dis. 2022; 74: 857-64. http://dx.doi.org/10.1093/cid/ciab542. [PubMed] [Google Scholar]
Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard J-P, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV
antiretroviral treatment. Expert Opin Drug Saf [Internet]. 2019; 18: 829–40. http://dx.doi.org/10.1080/14740338.2019.1644317. [PubMed] [Google Scholar]
Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Curr Opin Infect Dis [Internet]. 2021;34: 16–24. http://dx.doi.org/10.1097/qco.0000000000000695. [PubMed] [Google Scholar]
Baltazar-Díaz TA, Amador-Lara F, Andrade-Villanueva JF, GonzálezHernández LA, Cabrera-Silva RI, Sánchez-Reyes K, Álvarez-Zavala M, Valenzuela-Ramírez A, Del Toro-Arreola
S, Bueno-Topete MR. Gut Bacterial Communities in HIV-Infected Individuals with Metabolic Syndrome: Effects of the Therapy with Integrase Strand Transfer Inhibitor-Based and Protease InhibitorBased Regimens. Microorganisms. 2023; 11: 951. http://dx.doi.org/10.3390/microorganisms11040951. [PubMed] [Google Scholar]
Sonderup MW, Wainwright HC. Human immunodeficiency virus infection, antiretroviral therapy, and liver pathology. Gastroenterol Clin North Am [Internet]. 2017; 46: 327–43. http://dx.doi.org/10.1016/j.gtc.2017.01.007. [PubMed] [Google Scholar]
Pau AK, Penzak SR, Boyd SD, McLaughlin M, Morse CG. Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and
renal impairment: A management dilemma. Pharmacotherapy [Internet]. 2012; 32: e1–6. http://dx.doi.org/10.1002/phar.1003. [PubMed] [Google Scholar]
Han WM, Law MG, Choi JY, Ditangco R, Kumarasamy N, Chaiwarith R, Ly PS, Khusuwan S, Merati TP, Do CD, Yunihastuti E, Azwa I, Lee MP, Pham TN, Chan YJ, Kiertiburanakul S, Ng OT, Tanuma J, Pujari S, Zhang F, Gani Y, Mave V, Ross J, Avihingsanon A; TREAT Asia HIV Observational Database of IeDEA Asia-Pacific. Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Med. 2022; 23: 274-86. [PubMed] [Google Scholar]
Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol. 2014; 170:
R185-202. http://dx.doi.org/10.1530/eje-13-0967. [PubMed] [Google Scholar]
Buzón-Martín L. Weight gain in HIVinfected individuals using distinct antiretroviral drugs. AIDS Rev. 2020; 22: 158-67 http://dx.doi.org/10.24875/aidsrev.m20000036. [PubMed] [Google
Scholar]
Theron AJ, Anderson R, Madzime M, Rossouw TM, Steel HC, Meyer PWA, Cholo MC, Kwofie LLI, Feldman C, Tintinger GR. Pro-Inflammatory Interactions of Dolutegravir with
Human Neutrophils in an In Vitro Study. Molecules [Internet]. 2022; 27:9057. http://dx.doi.org/10.3390/molecules27249057. [PubMed] [Google Scholar]
Rebeiro PF, Emond B, Rossi C, Bookhart BK, Shah A, Caron-Lapointe G, Lafeuille MH, Donga P. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States. J Int AIDS Soc. 2023; 26: e26123http://dx.doi.org/10.1002/jia2.2612. [PubMed] [Google Scholar]
Ang LW, Ng OT, Boudville IC, Leo YS, Wong CS. An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore.
PLoS One [Internet]. 2021; 16:e0252320. http://dx.doi.org/10.1371/journal.pone.0252320. [PubMed] [Google Scholar]
Offor O, Utay N, Reynoso D, Somasunderam A, Currier J, Lake J. Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy. PLoS One [Internet]. 2018; 13:e0196395. http://dx.doi.org/10.1371/journal.pone.0196395. [PubMed] [Google Scholar]
Domingo P, Gutierrez Mdel M, GallegoEscuredo JM, Torres F, Mateo GM, Villarroya J, de los Santos I, Domingo JC, Villarroya F, Del Rio L, Estrada V, Giralt M. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. PLoS One. 2014; 9:
e89088. http://dx.doi.org/10.1371/journal.pone.0089088. [PubMed] [Google Scholar]
Young L, Wohl DA, Hyslop WB, Lee YZ, Napravnik S, Wilkin A. Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in AfricanAmericans initiating HIV therapy. HIV Clin Trials [Internet]. 2015; 16: 163–9. http://dx.doi.org/10.1179/1945577115y.0000000002. [PubMed] [Google Scholar]
Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; SecondLine Study Team. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One.. 2013;8: e77138. http://dx.doi.org/10.1371/journal.pone.0077138. [PubMed] [Google Scholar]
Hanttu A, Vuoti S, Kivelä P, Arkkila P, Lundbom N, Hakkarainen A, Lundbom J, Lehtimäki T, Viskari H, Lehtinen V, Pietiläinen KH, Sutinen J. Liver Fat, Adipose Tissue, and Body Composition
Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. AIDS Patient Care STDS. 2021; 35: 335-41. http://dx.doi.org/10.1089/apc.2021.0106. [PubMed] [Google Scholar]
van Wyk J, Ait-Khaled M, Santos J, Scholten S, Wohlfeiler M, Ajana F, Jones B, Nascimento MC, Tenorio AR, Smith DE, Wright J, Wynne B. Brief Report: Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. J Acquir Immune
Defic Syndr. 2021; 87: 794-800. http://dx.doi.org/10.1097/qai.0000000000002655. [PubMed] [Google Scholar]
Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact ofritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015; 60: 1842–51. Disponible en: http://dx.doi.org/10.1093/cid/civ193. [PubMed] [Google Scholar]
Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. Efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin DrugInvestig. 2015; 35: 211–9. http://dx.doi.org/10.1007/s40261-014-0266-2. [PubMed] [Google Scholar]
Allavena C, Volteau C, André-Garnier E, Guimard T, Hall N, Khatchatourian L, Morrier M, Billaud E, Rodallec A, Reliquet V, Jovelin T, Le Guen L, Perré P, Grégoire M, Raffi F. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIVinfected adults (SWAD study). Med Mal Infect. 2019;49: 505–10.http:/dx.doi.org/10.1016/j.medmal.2018.11.012. [PubMed] [Google Scholar]
Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG; ROCnRAL ANRS 157 Study Group. Maravirocplus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother. 2014;69: 1648–52. http://dx.doi.org/10.1093/jac/dkt536. [PubMed] [Google Scholar]
Depósito Legal: ppi201102ME3935 - ISSN: 2477-9369.
Copyright ©2012 ULA Todos los derechos reservados
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.